-
BMS-777607 for c-Met and MET Pathway Research
2026-08-15
BMS-777607 is a selective c-Met inhibitor for linking phospho-MET biology with practical cancer metastasis workflows. Its value extends to exploratory hiPSC-derived megakaryocyte studies, where the 2026 reference protocol provides a structured framework for testing small-molecule effects without overstating current evidence.
-
Hematoxylin and Eosin Staining Kit Guide
2026-08-14
The Hematoxylin and Eosin Staining Kit (SKU K1142) provides ready-to-use hematoxylin and eosin solutions for visualizing nuclei, cytoplasm, extracellular matrix, and overall tissue architecture in research specimens. It is suitable for histopathological and cytological workflows involving paraffin-embedded or frozen sections, but it is intended for research use only and not for diagnostic or medical testing.
-
ECL Western Blotting Substrate: Practical Guide
2026-08-14
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive reagent for detecting HRP-labeled proteins on immunoblots using X-ray film or CCD imaging. It is intended for HRP chemiluminescence workflows, not fluorescent or radioisotopic assays, and the prepared solution should be used promptly after preparation.
-
OMV-Displayed mRNA Antigens for Tumor Vaccines
2026-08-13
This study developed genetically engineered outer membrane vesicles (OMVs) that rapidly capture sequence-tagged mRNA antigens, promote dendritic-cell delivery, and support endosomal escape for cross-presentation. The platform produced antitumor responses in mouse melanoma and colon cancer models, while its modular Plug-and-Display design addresses a key logistical challenge in personalized mRNA vaccination.
-
Ibuprofen and Naproxen Synthesis: Recent Advances
2026-08-13
The review by Ha and Paek maps how modern synthetic chemistry has advanced the preparation of ibuprofen and naproxen through shorter, asymmetric, scalable, and continuous-flow routes. Its main practical contribution is to show that synthesis optimization is not only about yield, but also about stereochemical control, process safety, scale-up, and access to improved derivatives for nonsteroidal anti-inflammatory drug research.
-
Intravesical p21 mRNA–LNP Therapy in Bladder Cancer
2026-08-12
A 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, disrupted cell-cycle control, limited orthotopic tumor growth, and produced strong bladder-localized expression with limited transient systemic distribution in mice.
-
Berberine, RXRα/PPARγ, and SASP in Atherosclerosis
2026-08-12
The reference study identifies an RXRα/PPARγ/NEDD4 axis through which berberine suppresses SASP-associated inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of mouse disease modeling, foam-cell assays, transcriptomic profiling, and macrophage-specific RXRα knockdown provides a mechanistic framework for studying inflammatory vascular aging.
-
How Dual-Action Inhibitors Tune p38α Dephosphorylation
2026-08-11
The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can stabilize an activation-loop conformation that accelerates dephosphorylation by WIP1. This structural mechanism provides a framework for interpreting p38 MAPK signaling pathway modulation and for designing assays that distinguish catalytic inhibition from phosphatase-assisted signal termination.
-
H5N1 mRNA Vaccine Protects Lactating Dairy Cows
2026-08-11
A hemagglutinin-encoding mRNA–lipid nanoparticle vaccine protected lactating dairy cows from a high-dose H5N1 challenge and showed durable protection well beyond the initial immune response. The study provides important in vivo evidence for mRNA vaccination in a production-animal setting while also highlighting the need to define correlates of protection and manufacturing details.
-
GTP Solution for mRNA-LNP Workflows
2026-08-10
Learn how a defined 100 mM GTP stock supports reproducible in vitro transcription, RNA quality control, and mRNA-LNP development. The workflow connects nucleotide handling at the bench with localized p21 mRNA delivery research in bladder cancer while emphasizing practical optimization and troubleshooting.
-
L-Glutathione Reduced as a Redox Assay Tool
2026-08-09
L-Glutathione Reduced is more than a generic antioxidant: it is a controllable reagent for separating redox state, metabolism, and assay readouts. This article connects its chemistry and handling to GOT1-focused pancreatic cancer research while defining what the evidence does—and does not—show.
-
Recombinant Mouse IFN-γ for MASH-HCC Assays
2026-08-08
Use Recombinant Mouse IFN-γ to create a controlled immune-activation layer in MASH-HCC antigen-presentation experiments. This guide connects dose-controlled cytokine stimulation with bile acid, NLRC5, MHC-I, macrophage, and T-cell readouts while providing practical optimization and troubleshooting strategies.
-
Regorafenib (BAY 73-4506) Assay Guide
2026-08-07
A scenario-based laboratory guide to using Regorafenib (BAY 73-4506), SKU A8236, in viability, proliferation, migration, invasion, and angiogenesis experiments. It connects formulation, concentration selection, assay interpretation, and vendor-selection decisions to published melanoma findings and product-documented kinase activity.
-
Carbenoxolone disodium: Technical Use in 11β-HSD Inhibition
2026-08-07
Carbenoxolone disodium is a potent 11β-hydroxysteroid dehydrogenase inhibitor designed for dissecting glucocorticoid signaling, corticosterone metabolism, and gap junction communication in cell and tissue-based models. It is not intended for in vivo efficacy studies or for workflows requiring rigorous control over off-target effects.
-
XAV-939: Precision Tankyrase Inhibition for Wnt Pathway Rese
2026-08-06
XAV-939 (NVP-XAV939) stands out as a potent, reliable tankyrase inhibitor for dissecting Wnt/β-catenin signaling in disease models including cancer, fibrosis, and bone biology. This guide delivers actionable protocol details, troubleshooting insights, and cross-domain expertise, empowering researchers to achieve reproducible results with APExBIO’s XAV-939.